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Hedgehog (Hh) proteins regulate development and tissue homeostasis, but their role in
atopic dermatitis (AD) remains unknown. We found that on induction of mouse AD, Sonic
Hedgehog (Shh) expression in skin and Hh pathway action in skin T cells were increased.
Shh signaling reduced AD pathology and the levels of Shh expression determined disease
severity. Hh-mediated transcription in skin T cells in AD-induced mice increased Treg
populations and their suppressive function through increased active transforming growth
factor–b (TGF-b) in Treg signaling to skin T effector populations to reduce disease
progression and pathology. RNA sequencing of skin CD4+ T cells from AD-induced mice
demonstrated that Hh signaling increased expression of immunoregulatory genes and
reduced expression of inflammatory and chemokine genes. Addition of recombinant Shh to
cultures of naive human CD4+ T cells in iTreg culture conditions increased FOXP3
expression. Our findings establish an important role for Shh upregulation in preventing AD,
by increased Gli-driven, Treg cell–mediated immune suppression, paving the way for a
potential new therapeutic strategy.
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Introduction
Skin is in direct contact with the environment and acts as protective 
barrier from mechanical injuries and infections. Disruption of skin 
homeostasis and barrier function together with immune dysregula-
tion result in inflammatory diseases of the skin, such as atopic der-
matitis (AD), a chronic inflammatory disease with complex etiology 
characterized by dry scaly skin lesions and pruritus (1). The mecha-
nisms that cause AD remain controversial, but Filaggrin, a terminal 
differentiation marker of keratinocytes, is important for skin barrier 
formation, and its deficiency promotes immune alterations which 
contribute to AD (2). Skin inflammation in AD changes through time, 
with expanded T helper 2 (Th2) and Th17 responses at early stages, 
and a partial switch to a Th1 response during chronic stages (1–3). 
CD4+CD25+Foxp3+ Tregs are abundant in skin, and in inflammation 
they infiltrate the dermis but lose their immunoregulatory function, 
further enhancing the inflammatory response (1, 4–8). The reasons 
why the CD4+CD25+Foxp3+ population in skin fails to suppress the 
immune response in AD is unclear, so identification of skin factors 
that promote immune regulation is important to preventing AD.
Here we investigate Hh signaling in chronic AD using a mouse 
model of hapten-induced dermatitis, with all characteristics of the 
disease. The Hh proteins Sonic (Shh), Dessert (Dhh), and Indian 
(Ihh) are morphogens that share a common signaling pathway and 
regulate development and tissue homeostasis (9–11). Binding to 
their receptor Patched1 (Ptch1) initiates the pathway by relieving 
Smoothened (Smo) inhibition. At the end of the pathway are the 
Gli transcription factors (Gli1, Gli2, and Gli3), which bind DNA at 
consensus Gli-binding sites. Gli1 acts only as a transcriptional acti-
vator, whereas Gli2 and Gli3 function as activators of transcription 
in the presence of Hh signaling or repressors in its absence, with 
some redundant or partially overlapping functions.
Shh is expressed in hair follicles and dysregulated Hh signaling 
in skin leads to basal cell carcinoma (BCC) (12, 13). Hh signaling 
regulates T cell development and T cell receptor (TCR) repertoire 
selection (14–21). Gli1 and Gli2 are expressed in peripheral T cells 
and Hh signaling can impair T cell activation (15, 17, 18, 22–25).
Here we use constitutive and conditional mutant mice to inves-
tigate epithelium-lymphocyte cross-talk in AD. We show that Shh 
upregulation and increased Hh signaling to T cells in skin play a 
critical role in preventing skin inflammation on induction of chron-
ic AD. Thus, our study dissects a previously unknown signaling 
mechanism, mediated by the skin-derived morphogen Shh, which 
is required for and promotes Treg-dependent skin homeostasis.
Results
Induction of AD upregulates Shh in skin and increases Hh pathway 
activation in skin T cells. We used an oxazolone-induced (Oxa- 
induced) model of extrinsic AD in mice (Figure 1A), which gen-
erates T cell–driven skin inflammation in the ears, with all the 
features of chronic human AD, including swelling, T cell infiltra-
tion, and IgE and cytokine production (Supplemental Figure 1, 
A–E) (26). We examined expression of Hh pathway components in 
inflamed skin from Oxa-treated WT mice and in skin from control 
WT mice. Shh mRNA was significantly elevated in Oxa-treated 
compared with untreated skin, whereas there was no significant 
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of disease, their skin showed significantly lower Shh expression 
than WT mice (Figure 2A). The Shh+/– mice developed aggravated 
disease compared with WT, with increased epidermal thickness 
and aggravated hyperkeratosis and parakeratosis (Figure 2B). The 
Oxa-treated Shh+/– mice showed higher serum IgE, increased Il4 
expression in skin, and increased skin infiltration of CD4+ T cells 
compared with Oxa-treated WT mice (Figure 2, C–E). A greater 
proportion of skin CD4+ T cells expressed IFN-γ and IL-13 in the 
Shh+/–, whereas the proportion of cells that expressed IL-17 was 
decreased, consistent with faster disease progression (Figure 2F). 
Thus, the lower level of Shh expression in the skin of Shh+/– mice 
led to more severe disease.
To confirm the theory that the level of Shh in the skin deter-
mines severity of AD, we wanted to induce AD in mice with high-
er expression of Shh in skin than WT. As Gli3 can reduce Shh 
expression and Shh-signaling (20, 28) we tested if Shh expression 
is increased in skin in constitutive Gli3+/– compared with WT. Shh 
expression was significantly higher in untreated Gli3+/– compared 
with WT skin (Figure 2G), confirming that this was a suitable 
mutant to test the impact of elevated levels of Shh on induction of 
AD. After Oxa treatment, Gli3+/– mice had attenuated epidermal 
and dermal thickening with decreased hyperkeratosis and par-
akeratosis compared with WT mice (Figure 2H), and serum IgE 
levels were significantly decreased (Figure 2I). Significantly lower 
Il4 and Il13 expression and higher Shh expression were observed 
in the Oxa-treated ears of the Gli3+/– group compared with those 
of the WT mice (Figure 2J). Although we did not detect differences 
in numbers of skin CD4+ and CD8+ T cells (Figure 2K), analysis 
of intracellular cytokine expression showed that the proportion 
of T cells that expressed the Th2 cytokines IL-4 and IL-13 was 
decreased in Oxa-treated Gli3+/– compared with Oxa-treated WT 
mice (Figure 2L). These experiments therefore showed that con-
stitutive Gli3 mutation led to increased Shh expression in skin and 
was protective against induction of AD.
Pharmacologic blockade of Smoothened caused exacerbation 
of Oxa-induced AD and Shh downregulation. Given that altering 
levels of Shh in skin by constitutive genetic mutation changed 
disease outcome on AD induction, we next investigated in WT 
mice, whether systemic inhibition of the Hh signaling pathway 
would also have a detrimental effect on skin pathology on AD 
induction, using the PF-04449913 Smo-inhibitor (Smo-inh) 
(29, 30). WT mice received i.p. injections of either Smo-inh or 
DMSO (vehicle-control) daily throughout the Oxa protocol (Fig-
ure 3A). Administration of Smo-inh to Oxa-treated mice caused 
a significant increase in ear and dermal thickness (Figure 3, B–C) 
compared with Oxa-treated controls, whereas untreated skin of 
Smo-inh- and DMSO-injected mice were indistinguishable and 
contained similar proportions and numbers of skin immune cells 
(Supplemental Figure 2, A and B). Serum IgE was increased in 
Oxa-treated Smo-inh–injected mice compared with control mice 
(Figure 3D), consistent with increased atopic disease. Shh tran-
script levels from Oxa-treated ear tissue were lower in Smo-inh–
injected mice compared with control, whereas in the absence of 
Oxa treatment there was no difference in Shh expression in skin 
of Smo-inh– and DMSO-injected mice (Figure 3E). Smo inhibition 
significantly increased innate immune cell populations in skin of 
Oxa-treated mice (Figure 3F). We did not observe significant dif-
change in Dhh and Ihh transcripts (Figure 1B). Ptch1 and Gli1, which 
are both Hh pathway components and target genes (9), were also 
upregulated in Oxa-treated skin compared with control (Figure 
1B). Immunofluorescence staining of ear skin revealed increasing 
expression of Shh in dermis and epidermis of mice with AD, from 
day 8 of the protocol (Figure 1C). In contrast to Oxa treatment of 
WT mice, Oxa treatment of lymphocyte-deficient Rag1-KO mice 
failed to induce ear swelling (Figure 1D), downregulation of Fil-
aggrin, or upregulation of Ifng and Il4, confirming the lymphocyte 
dependence of disease induction (Supplemental Figure 1F). Shh 
was not upregulated in the skin of the Rag1-KO mice, indicat-
ing that the increased expression of Shh on hapten treatment is 
dependent on lymphocyte-driven inflammation (Figure 1E).
To test if the Hh signaling pathway is active in skin T cells 
after AD induction, we used Gli binding site (GBS)–GFP reporter 
transgenic mice (27) to measure the proportion of T cells that show 
active Gli-mediated transcription. The percentage of CD3+ T cells 
that expressed GFP was higher in Oxa-treated skin compared with 
control (Figure 1F). There were significantly more GFP+CD8+ and 
GFP+CD4+ T cells, with elevated MFI of GFP in CD4+ T cells in 
Oxa-treated skin (Figure 1, F–G), indicating that not only did more 
skin CD4+ T cells undergo active Hh signaling after disease induc-
tion, but also that the level of Hh pathway activation was higher in 
individual CD4+ T cells. There was therefore an increase in both 
Shh expression in skin and in Gli-mediated transcription in skin T 
cells from Oxa-treated mice, suggesting that Hh signaling might 
be involved in AD.
Shh mutation increases severity of AD whereas Gli3 mutation ame-
liorates chronic AD. Given that Shh was upregulated and Hh signal-
ing was increased after AD induction, we examined directly the 
impact of Shh in AD, using constitutive Shh+/– mice. On induction 
Figure 1. Shh upregulation and in vivo activation of the Hh signaling 
pathway upon induction of AD. Black circles, control mice; red squares, 
Oxa-treated mice. Each symbol represents an individual animal. (A) Sen-
sitization and challenge scheme of Oxa treatment. (B) mRNA expression 
by QRT-PCR of Hh signaling components in whole ear skin homogenates 
from untreated WT and Oxa-treated WT mice. Data from 2 independent 
experiments. (C) Representative immunofluorescence staining images of 
Shh (red) expression in frozen skin sections from untreated WT (day 0) 
and Oxa-treated WT mice on days 6, 8, 10, 12, and 14 after initiation of the 
Oxa protocol. DAPI-stained nuclei are shown in blue. Scale bar: 100 μm (n 
= 5 mice per group). (D) Time course of ear thickness from Rag1-KO control 
(blue), Oxa-treated Rag1-KO (green), WT control (black), and Oxa-treated 
WT (red) mice (n = 6 per group). (E) Representative immunofluorescence 
staining images of Shh (red) expression in frozen skin sections from 
untreated Rag1-KO and Oxa-treated Rag1-KO mice on termination (day 
14). DAPI-stained nuclei are in blue. Scale bar: 100 μm (n = 3 mice per 
group). Plot shows comparison of Shh mRNA expression in whole ear 
homogenates from control untreated Rag1-KO (n = 3) and Oxa-treated 
Rag1-KO (n = 3) with equivalent Shh expression data from WT from B. Data 
from 2 independent experiments. (F) Representative density plots of GFP 
expression in skin CD3+ T cells from untreated and Oxa-treated GBS-GFP 
transgenic mice, giving percentage of cells in GFP+ region shown. Plots 
show number of skin GFP+CD4+ and GFP+CD8+ T cells isolated from ears 
from untreated and Oxa-treated GBS-GFP transgenic mice. (G) MFI of GFP 
in skin GFP+CD4+ and GFP+CD8+ T cells from untreated and Oxa-treated 
GBS-GFP transgenic mice. In B, E–G, 2-tailed unpaired Student’s t test was 
used; in D, ANOVA was used. Plots show mean ± SEM. *P < 0.05, **P < 
0.01, ***P < 0.001, ****P < 0.0001.
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was decreased, whereas Il13 and Il4 expression were increased 
in skin from Oxa-treated Gli2ΔC2 mice compared with skin from 
Oxa-treated WT mice (Figure 4C). Protein levels of IFN-γ, TNF-α, 
and IL-6, a proinflammatory cytokine secreted by keratinocytes 
that contributes to AD (31), were higher in Oxa-treated Gli2ΔC2 
skin compared with skin from Oxa-treated WT (Figure 4D).
We found significantly higher proportions of CD4 and CD8 
T cells and numbers of CD8+ T cells in ears from Oxa-treated 
Gli2ΔC2 mice compared with ears from Oxa-treated WT mice 
(Figure 4E). In draining lymph nodes (dLNs) there was a signifi-
cant increase in the proportion of CD8+ T cells, and the percentage 
of CD69+ cells was higher in both CD4+ and CD8+ populations in 
Oxa-treated Gli2ΔC2 mice compared with Oxa-treated WT mice 
(Supplemental Figure 3, A and B). Analysis of cytokine produc-
tion by intracellular staining showed that IFN-γ production was 
significantly elevated in both Gli2ΔC2 CD4+ and CD8+ skin popu-
lations, and a significantly higher proportion of skin CD4+ T cells 
produced IL-5 and IL-17 compared with WT (Figure 4, F–G). Thus, 
T cell autonomous inhibition of Hh pathway activation promoted 
induction of skin inflammation and chronic AD, showing that in 
normal WT skin, Hh pathway activation in T cells protects against 
disease induction and severity.
Gli2-mediated transcription in T cells protects against induction 
of AD. To test if elevated Hh pathway activation in T cells can pro-
tect against AD, we induced AD in mice in which Gli2-mediated 
transcription is constitutively activated in T cells only: lck-Gli2ΔN2 
transgenic mice express a truncated form of Gli2 that can func-
tion only as an activator of transcription, causing constitutive Hh- 
mediated transcription in all T cells (17). While untreated ears were 
indistinguishable, Oxa treatment resulted in significantly lower ear 
thickness from day 7 onward in Gli2ΔN2 mice compared with WT 
mice, and skin pathology was ameliorated, with diminished dermal 
and epidermal thickening (Figure 5, A and B). Expression of Il4 was 
lower and Filaggrin was higher in Oxa-treated Gli2ΔN2 ears com-
pared with WT ears, indicative of better barrier function and lower 
skin pathology, and we did not detect a difference in Shh expres-
sion between WT and Gli2ΔN2 groups (Figure 5C). Oxa-treated 
Gli2ΔN2 ears showed significantly decreased IL-13 protein levels 
compared with WT ears (Figure 5D). In AD, Th1 cytokines stimu-
late keratinocytes to produce the proinflammatory cytokines IL-1β 
and TNF-α, and TNF-α drives IL-1β production by mast cells (32). 
These proteins were increased in Oxa-treated skin compared with 
untreated experimental controls, but the Gli2ΔN2 Oxa-treated 
mice showed significantly lower expression of both cytokines com-
pared with WT mice (Figure 5D). Analysis of T cell skin infiltration 
did not reveal differences in number of skin CD4+ T cells, but there 
was a significant reduction in skin CD8+ T cells in the Oxa-treated 
Gli2ΔN2 group compared with the WT group (Figure 5E).
Analysis of T cells from dLNs showed significantly reduced 
CD4+ and CD8+ populations in Oxa-treated Gli2ΔN2 compared 
with Oxa-treated WT mice (Supplemental Figure 4A). The propor-
tion of naive (CD62L+CD44–) CD4+ T cells was elevated, whereas 
the T effector memory (Teff) (CD62L–CD44+) and T central mem-
ory (Tcm) (CD62L+CD44+) cells were decreased in both CD4+ and 
CD8+ populations in dLNs from Oxa-treated Gli2ΔN2 compared 
with Oxa-treated WT mice (Supplemental Figure 4B), consis-
tent with the fact that Teff and Tcm populations are increased 
ferences in proportion or numbers of CD4+ and CD8+ T cells or in 
their expression of IL-4 and IL-13 (Supplemental Figure 2, C and 
D), although a significantly greater proportion of CD4+ expressed 
IFN-γ and IL-17 and CD8+ T cells expressed IFN-γ (Figure 3, G–H) 
after Smo-inh administration compared with control. Smo-inh 
administration led to a significant reduction in the skin CD4+ 
CD25+Foxp3+ Treg population in the Oxa-treated mice (Figure 3I).
Thus, systemic Smo inhibition in WT mice caused increased 
skin inflammation on induction of AD in vivo and led to reduced 
Shh upregulation in skin tissue, confirming that Shh signaling is 
important in protecting against AD in WT animals.
Constitutive inhibition of Hh-mediated transcription in T cells 
promotes induction of skin inflammation. To investigate the cellu-
lar mechanism of the protective role of Hh signaling in AD, we 
used T cell–specific mutants to test if Shh was signaling directly 
or indirectly to T cells, since AD is a T cell–dependent disease. 
We induced AD in mice in which Gli2-mediated transcription is 
constitutively inhibited in T cells only: lck-Gli2ΔC2 transgenic 
mice express a truncated form of Gli2 that can function only as a 
transcriptional repressor, and by binding consensus GBSs inhibits 
normal Hh-mediated transcription, rendering T cells refractory to 
upregulation of Ptch1 on Shh treatment (18). After Oxa treatment, 
Gli2ΔC2 mice showed significantly increased ear thickness com-
pared with WT mice (Figure 4A). Although nontreated controls of 
both groups were similar, Oxa-treated Gli2ΔC2 mice had increased 
dermal and epidermal thickness compared with their Oxa-treated 
WT littermates (Figure 4B). Shh expression in skin was not signifi-
cantly different, consistent with the fact that the genetic modifica-
tion in these animals is limited to T cells only, which have not been 
shown to express Shh (20, 23). In contrast, Filaggrin expression 
Figure 2. Shh mutation aggravates but Gli3 mutation ameliorates chronic 
AD. (A–F) Oxa-treated Shh+/– mice (red) and WT littermates (black). (A) 
Shh expression (QRT-PCR) in ear homogenates from Oxa-treated WT 
and Shh+/– mice. (B) Representative H&E images of ear sections from 
Oxa-treated WT (n = 4) and Shh+/– (n = 4) mice (day 14), showing areas 
of hyperkeratosis (green arrows) and parakeratosis (white arrows). Scale 
bar: 100 μm. Plots show dermal and epidermal thickness. (C) Serum IgE 
concentration (ELISA) from Oxa-treated WT and Shh+/– mice. (D) Il4 and 
Il13 expression (QRT-PCR) in whole ear homogenates from Oxa-treated WT 
and Shh+/– mice. (E) Contour plot shows CD4 and CD8 expression, gated on 
CD45+CD3+γδTCR– cells from ears of Oxa-treated WT and Shh+/– mice. Plots 
show number of CD4+ and CD8+ T cells isolated from ears. (F) Percentage of 
skin T cells from Oxa-treated WT and Shh+/– mice that express IFN-γ, IL-4, 
IL-13, and IL-17, measured by flow cytometry. (G) Shh expression (QRT-PCR) 
in whole ear homogenates from untreated WT (black) and Gli3+/– (red) 
mice. (H–L) Data from 2 independent experiments using Oxa-treated WT 
(black) and Gli3+/– (red) littermates. (H) Representative H&E images of ear 
sections from untreated (baseline) and Oxa-treated WT and Gli3+/– mice 
(day 14), showing areas of hyperkeratosis (green arrows) and parakeratosis 
(white arrows). Scale bar: 100 μm. Plots show dermal and epidermal thick-
ness. (I) Serum IgE concentration (ELISA) from Oxa-treated WT and Gli3+/– 
mice. (J) Il4, Il13, and Shh expression (QRT-PCR) in whole ear homogenates 
from Oxa-treated WT and Gli3+/– mice. (K) Contour plot shows CD4 and 
CD8 expression, gated on CD45+CD3+γδTCR– cells isolated from Oxa-treated 
ears from WT and Gli3+/– mice. Plots show number of CD4+ and CD8+ T cells 
isolated from ears. (L) Percentage of skin T cells from Oxa-treated WT 
and Gli3+/– mice that express IFN-γ, IL-4, IL-13, and IL-17, measured by flow 
cytometry. Plots show mean ± SEM; each symbol represents an individual 
animal; 2-tailed unpaired Student’s t test. *P < 0.05, **P < 0.01,  
***P < 0.001, ****P < 0.0001.
The Journal of Clinical Investigation R E S E A R C H  A R T I C L E
3 1 5 8 jci.org   Volume 129   Number 8   August 2019
in AD patients (33). Intracellular cytokine analysis showed that 
in Oxa-treated Gli2ΔN2 skin, a lower proportion of CD4+ T cells 
expressed IFN-γ and IL-13 and a lower proportion of CD8+ T cells 
expressed IFN-γ compared with WT skin, whereas differences in 
the proportion of cells that expressed IL-4, IL-5, or IL-17 were not 
statistically significant (Figure 5, F–G).
Thus, conditional Gli2-mediated transcription in T cells 
impaired induction of AD and rescued skin pathology, showing 
that elevated T cell autonomous Hh pathway activation can, and is 
sufficient, to protect against skin inflammation in AD.
Gli2 controls transcription of inflammation- and immune regu-
lation–related genes. As the antiinflammatory action of Shh in AD 
is T cell dependent, we investigated the mechanisms of Shh’s pro-
tective role in AD by RNA-sequencing (RNA-seq) FACS-sorted 
CD4+ T cells isolated from the skin of Oxa-treated WT, Gli2ΔN2, 
and Gli2ΔC2 mice.
Figure 3. Pharmacological Smo inhibition exacerbates AD in WT mice. Data from 2 independent experiments with 7 Oxa-treated WT mice per group 
unless otherwise stated. Control (black, DMSO-only–injected) and Smo-inh–injected (red) mice; each symbol represents an individual animal. (A) Scheme 
of Oxa administration with i.p. Smo-inh or DMSO injection. (B) Plot shows ear thickness from Oxa-treated control and Smo-inh–injected groups. (C) 
Representative H&E images of ear sections from Oxa-treated WT mice injected either with DMSO only (left image) or Smo-inh (right) at termination 
(day 14). Scale bar: 100 μm. Plots show dermal and epidermal thickness of Oxa-treated WT without Smo-inh (DMSO-only control) and with Smo-inh on 
day 14. (D) Serum IgE concentration from Oxa-treated control and Smo-inh–injected mice measured by ELISA. (E) Shh expression (QRT-PCR) in whole ear 
homogenates from Oxa-treated and Oxa-untreated mice without Smo-inh injection (DMSO-only control) and with Smo-inh injection. (F) Percentage and 
number of skin leukocytes (CD45+), macrophages (Mϕ; CD45+CD11b+F4/80+) and eosinophils (Eos; CD45+CD11b+SiglecF+) from ear skin from Oxa-treated 
control (DMSO only) and Smo-inh–injected mice. (G) Percentage of skin CD4+ T cells that expressed IFN-γ and IL-17 from Oxa-treated control (DMSO only) 
and Smo-inh–injected mice. (H) Percentage of skin CD8+ T cells that expressed IFN-γ and IL-17 from Oxa-treated control (without Smo-inh, DMSO only) and 
Smo-inh–injected mice. (I) Percentage of skin CD4+ T cells that are Treg (CD3+CD25+icFoxp3+) from Oxa-treated control (without Smo-inh, DMSO only) and 
Smo-inh–injected mice. Plots are mean ± SEM; 2-tailed unpaired Student’s t test. *P < 0.05, **P < 0.01, and ***P < 0.001.
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Figure 4. Exacerbated skin inflammation on induction of AD when Hh pathway 
activation in T cells is inhibited. AD was induced in WT (black) and Gli2ΔC2 (red) mice 
by Oxa treatment. (A) Mean ± SEM ear thickness from Oxa-treated WT and Gli2ΔC2 
mice on days 5 to 14 after initiation of Oxa treatment. (B) Representative H&E images 
of skin sections from untreated (baseline) and Oxa-treated WT and Gli2ΔC2 (day 14) 
mice. Scale bar: 100 μm. Plots show dermal (upper) and epidermal (lower) thickness 
for control and Oxa-treated groups (day 14); 2-way ANOVA. (C) Shh, Filaggrin, Il4, and 
Il13 expression (QRT-PCR) in ear homogenates from Oxa-treated WT and Gli2ΔC2 mice. 
Data from 2 independent experiments. (D) Cytokine concentration in skin supernatants 
from untreated and Oxa-treated WT and Gli2ΔC2 mice. Data from 2 independent exper-
iments, analyzed by 2-way ANOVA. (E–G) Data from 2 independent experiments with 
at least 6 mice per group. (E) Percentage and number from ear of skin CD4+ and CD8+ 
T cells from Oxa-treated WT and Gli2ΔC2 mice. (F) Percentage of skin CD4+ T cells that 
express cytokines in Oxa-treated WT and Gli2ΔC2 mice. (G) Percentage of skin CD8+ T 
cells that express IFN-γ and IL-17. Two-tailed unpaired Student’s t test; 2-way ANOVA 
(B, D). Plots are mean ± SEM; each symbol represents an individual animal. *P < 0.05, 
**P < 0.01, ***P < 0.001.
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compared with WT samples, whereas Tgif1, a negative regulator of 
TGF-β (37), inflammatory (Stat4, Il4ra), and migratory (Ccr7) genes 
were downregulated in the Gli2ΔN2 data sets compared with WT 
samples. Ptgs2, which is both a Hh target gene and a positive regula-
tor of Tregs (38), was upregulated in Gli2ΔN2 samples.
Shh and Gli3 expression was not detected in skin CD4+ T cells 
in any data set (Supplemental Table 3), consistent with previous 
studies showing Shh and Gli3 expression in epithelial cells but not 
mouse T cells (15, 20, 23, 39–41).
Thus, on induction of AD, elevated levels of Hh-mediat-
ed transcription in skin CD4+ T cells promoted expression of 
immune-regulatory genes and repressed inflammation genes, 
whereas reduction of Hh-mediated transcription in T cells to 
below WT levels promoted expression of inflammation genes.
Hedgehog signaling is required for activation of skin Treg popula-
tions. As the RNA-seq revealed involvement of immune-regulatory 
genes, we tested if Hh signaling influences skin and peripheral Treg 
populations after AD induction. After Oxa treatment, we observed 
a significant increase in CD4+CD25+Foxp3+ (Tregs) in Gli2ΔN2 and 
Gli3+/– skin compared with WT skin, and a significant reduction 
in the proportion of Tregs in Gli2ΔC2 and Shh+/– skin compared 
with WT skin (Figure 6, D and E). Likewise, Tregs in dLNs from 
Oxa-treated Gli2ΔC2 mice were significantly decreased compared 
with WT mice (Supplemental Figure 5A).
DEGs between Gli2ΔN2 and Gli2ΔC2 data sets included genes 
involved in Treg function (Klrg1, Il10, Tgfb1, and Areg) which were 
significantly upregulated in Gli2ΔN2 compared with Gli2ΔC2 
samples, whereas genes that negatively regulate TGF-β signaling 
or Treg function (Tgif1, Crem, Crbn) were more highly expressed 
in the Gli2ΔC2 data sets (Figure 6F).
The Tregs in Oxa-treated Gli2ΔN2 dLNs displayed a more 
activated and suppressive phenotype than their WT counter-
parts, with increased expression of Klrg1, CTLA4, CD44, and 
Ki67, whereas inhibition of normal Hh-mediated transcription in 
Oxa-treated Gli2ΔC2 dLNs led to a significant decrease in Klrg1, 
CTLA4, and CD44 expression on Tregs, compared with WT dLNs 
(Supplemental Figure 5, B and C). 
Il10 and Tgfb1 were differentially expressed between geno-
types in CD4+ T cells isolated from Oxa-treated skin (Figure 6F), 
and as these genes are also expressed by other immune cell types, 
we evaluated their expression in whole skin (ear tissue). Oxa-treat-
ed Gli2ΔN2 mice showed higher Il10 expression in ear tissue than 
WT mice, whereas Oxa-treated Gli2ΔC2 mice showed lower Tgfb1 
expression in ear tissue than WT mice (Figure 6G), indicating that 
inhibition of Hh-mediated transcription specifically in T cells is 
sufficient to reduce overall expression of the gene encoding this 
important antiinflammatory cytokine in the skin.
Given that Tregs from Gli2ΔN2 mice had a stronger immuno-
regulatory phenotype than Tregs from WT or Gli2ΔC2 mice (Fig-
ure 6, A–C and F, and Supplemental Figure 5, B and C) we com-
pared their in vitro immunosuppressive activity in coculture with 
WT cells (Figure 6H). Tregs isolated from spleen of Oxa-treated 
Gli2ΔC2 mice had lower in vitro immunosuppressive activity than 
Tregs from Oxa-treated WT mice, so that not only was the pheno-
typically defined active Treg population reduced, but its function 
was compromised by inhibition of Gli-mediated transcription 
(Figure 6H). In contrast, Tregs isolated from spleen of Oxa-treated 
First, to evaluate the RNA-seq data sets in an unbiased way, 
we carried out principal component analysis (PCA), a multivari-
ate analysis, which can be used to segregate genome-wide tran-
scription data sets according to variability in transcript expres-
sion values and cluster data sets to detect dominant patterns of 
gene expression, represented by the principal components (PC). 
PCA segregated our data sets by genotype on PC1 and PC2. PC1 
accounted for 33% of variability and separated WT from Gli2ΔN2, 
whereas PC2 accounted for 20% of variability and separated WT 
from Gli2ΔC2 (Figure 6A). Genes that contributed strongly to 
these axes included Stat4, Tbx21, and Ifngr1, which were upreg-
ulated in samples from Gli2ΔC2 mice (represented by negative 
scores in PC2 axis) and downregulated in samples from Gli2ΔN2 
mice (negative scores in PC1 axis). Additionally, Foxp3, Il10ra, and 
Plcb3 contributed strongly to PC1 and PC2, and showed increased 
transcription in Gli2ΔN2 mice compared with WT mice, and 
decreased transcription in Gli2ΔC2 mice compared with WT mice. 
Thus, PCA highlighted differences in expression of genes involved 
in inflammatory T cell responses and immune regulation.
To further investigate the genes that are implicated in func-
tional differences between genotypes in chronic AD, we intersect-
ed differentially expressed genes (DEGs) identified by Ebayes 
statistics between WT and each transgenic sample with genes that 
contributed to the relevant PC axis for that transgenic sample. For 
the comparison between Gli2ΔC2 and WT mice, 796 DEGs from 
the intersection (Supplemental Table 1) were clustered in a heat-
map (Figure 6B). Hh pathway and target genes (Hus1, Stmn1, Kif7, 
Smo) (9, 28, 34, 35) were downregulated in Gli2ΔC2 compared 
with WT mice, whereas genes involved in inflammation (Tnfrsf9, 
Il1a, Il12rb), migration (Ccr9, Cxcl16, Ccl20, Ccl24), and inhibition 
of immune regulation (Crbn) (36) were upregulated in Gli2ΔC2 
compared with WT mice.
For the comparison between Gli2ΔN2 and WT mice, 1681 
DEGs from the intersection genes (Supplemental Table 2) were 
clustered in a heatmap (Figure 6C). Hh pathway components, target 
genes (Ptch1, Gli2, Mafb) (9, 10, 34), and immune-regulatory genes 
(Tgfb1, Il10, Il10rb, Klrg1, Cd44) (6) were upregulated in Gli2ΔN2 
Figure 5. Conditional Gli2-mediated transcription in T cells reduces 
induction of chronic AD. AD was induced in WT (black) and Gli2ΔN2 (red) 
mice by Oxa treatment. (A) Mean ± SEM ear thickness from Oxa-treated 
WT (n = 8) and Gli2ΔN2 (n = 7) mice on days 5 to 14 of Oxa treatment. (B) 
Representative H&E images of skin sections from untreated (baseline) 
and Oxa-treated WT and Gli2ΔN2 mice on day 14. Scale bar: 100 μm. Plots 
show dermal and epidermal thickness of untreated and Oxa-treated WT 
and Gli2ΔN2 mice on day 14. Data from 2 independent experiments; 2-way 
ANOVA used in B. (C) Shh, Filaggrin, and Il4 expression (QRT-PCR) in 
ear homogenates from WT and Gli2ΔN2 mice. Data from 2 independent 
experiments. (D) Cytokine concentrations in ear skin supernatants from 
untreated and Oxa-treated WT and Gli2ΔN2. Data from 2 independent 
experiments; analysis by 2-way ANOVA. (E) Contour plots show CD4 and 
CD8 expression on skin cells from Oxa-treated WT and Gli2ΔN2 mice. Plots 
show number of skin CD4+ and CD8+ T cells isolated from ears. (F) Percent-
ages of skin CD4+ T cells that express cytokines in Oxa-treated WT and 
Gli2ΔN2 mice measured by flow cytometry. (G) Percentages of skin CD8+ T 
cells that express IFN-γ and IL-17. (E–G) Data were generated from 2 inde-
pendent experiments with at least 6 mice per group. Two-tailed unpaired 
Student’s t test; 2-way ANOVA (B, D). Plots are mean ± SEM; each symbol 
represents an individual animal. *P < 0.05, **P < 0.01, ***P < 0.001.
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control from day 7 of the Oxa protocol onwards, whereas adoptive 
transfer of Gli2ΔC2 Tregs had no impact on ear thickness (Figure 
7G). The number of CD4+ and CD8+ T cells in Oxa-treated recip-
ient ears was reduced by approximately 4-fold in the Gli2ΔN2 
adoptive transfer group compared with the control group, but was 
not significantly different between the Gli2ΔC2 adoptive transfer 
group and the control group (Figure 7H). The proportion of IL-17+ 
cells in the skin CD4+ population was significantly reduced in the 
Gli2ΔN2 adoptive transfer group compared with the control group 
(Supplemental Figure 5F), and the number of CD4+ cells isolated 
from Oxa-treated ears that expressed IFN-γ, IL-13, IL-4, and IL-17 
and the number of CD8+ cells that expressed IFN-γ and IL-17 were 
also significantly reduced in the Gli2ΔN2 adoptive transfer group, 
but were not different between Gli2ΔC2 adoptive transfer group 
compared with the control group (Figure 7, I–J). Whole ear tissue 
showed significantly lower expression of Il4 and higher expression 
of Tgfb1 in the Gli2ΔN2 adoptive transfer group compared with the 
control group, but expression of these genes was not significant-
ly different between the Gli2ΔC2 adoptive transfer group and the 
control group (Figure 7K). Interestingly, Shh expression was also 
significantly reduced in the Gli2ΔN2 adoptive transfer group com-
pared with the Gli2ΔC2 adoptive transfer group (Figure 7K), indi-
cating that the T cell autonomous immunoregulatory action of Hh 
signaling to induce Treg activity is sufficient to inhibit Shh upreg-
ulation in response to Oxa-induced inflammation.
Hh pathway activation in T cells activates TGF-β signaling for 
immune regulation. The adoptive transfer experiments showed 
both that Gli2-mediated transcription in T cells is essential for Treg 
immune-regulatory function and that Hh-driven immune-regula-
tory function is sufficient to inhibit AD induction (Figure 7, G–K). 
In addition, Tgfb1 was differentially expressed in RNA-seq data 
sets and in whole ear between Oxa-treated Gli2ΔN2 and Gli2ΔC2 
mice (Figure 6, F–G). Therefore, as TGF-β signals for induction, 
maintenance, and function of Tregs (42, 43), we evaluated TGF-β 
by staining against anti–latency associated peptide (anti-LAP) in 
skin populations from Oxa-treated Gli2ΔN2, Gli2ΔC2, and WT 
mice. LAP is derived from cleavage of the N-terminal of the TGF-β 
precursor protein and held on the cell surface, and its activation is 
crucial for the suppressive potential of Tregs and TGF-β function 
(44, 45). Non-Treg CD4+ T cells from Oxa-treated Gli2ΔN2 mice 
expressed significantly more LAP than WT mice, whereas the 
Oxa-treated Gli2ΔC2 mice showed a reduction in cell-surface LAP 
on CD45+ cells and non-Treg CD4+ T cells compared with WT mice 
(Figure 8A). Expression of LAP was increased on the Oxa-treated 
Gli2ΔN2 Treg population compared with WT Tregs, but signifi-
cantly reduced on the Gli2ΔC2 Treg population compared with 
WT Tregs (Figure 8B). We then measured the concentration of 
active TGF-β protein in supernatants from in vitro immunosup-
pressive assays between WT and Gli2ΔC2 Tregs (Figure 8C). WT 
CD4–Gli2ΔC2 Treg cocultures contained significantly less active 
TGF-β compared with WT CD4–WT Treg cocultures, consistent 
with the anti-LAP staining, RNA-seq expression profiles, and dis-
ease severity upon Oxa treatment when Gli2-mediated transcrip-
tion in T cells is inhibited.
Previous studies showed that Tregs fail to suppress T cells, 
which have a reduced ability to respond to TGF-β in mouse mod-
els of colitis and autoimmune encephalomyelitis (46–48). Given 
Gli2ΔN2 mice had higher immunosuppressive activity than 
Tregs from Oxa-treated WT mice (Figure 6H), consistent with 
their more activated phenotype (Figure 6, C and F, and Supple-
mental Figure 5, B and C).
To test in vivo the importance of Hh-driven Treg function in 
AD induction and progression, we depleted Tregs from Gli2ΔN2 
mice by anti-CD25 mAb injection before and during the Oxa 
protocol (Supplemental Figure 5D) and compared the outcome 
to control Oxa-treated Gli2ΔN2 mice that were injected with 
irrelevant IgG (Figure 7, A–F). Anti-CD25 injection significantly 
reduced the Treg population and led to increases in ear swelling 
and epidermal thickness, serum IgE, Il4 expression in ear skin, 
and the proportion of skin CD4+ T cells that expressed intracellu-
lar IFN-γ, IL-13, and IL-4 (Figure 7, A–E). The proportion of skin 
CD8+ T cells that expressed intracellular IFN-γ and IL-17 were 
also increased in the anti-CD25 group compared with the control 
group (Figure 7F). Depletion of the Treg population was therefore 
sufficient to increase induction of AD and inflammation on Oxa 
treatment in Gli2ΔN2 mice.
Next, to test the importance of Hh signaling in induction of Treg 
immunoregulatory function in AD in vivo, we compared the ability 
of CD4+CD25+ (Treg) cells purified from Oxa-treated Gli2ΔN2 or 
Gli2ΔC2 mice to inhibit AD induction and reduce disease severity 
and inflammation on adoptive transfer into Oxa-treated WT recip-
ients (Figure 7, G–K). Purified Tregs were injected into the recipi-
ents 2 days before initiation of the Oxa protocol and again on day 7 
(Supplemental Figure 5E). Adoptive transfer of Gli2ΔN2 Tregs sig-
nificantly reduced ear thickness compared with Oxa-treated WT 
Figure 6. Transcriptional mechanisms of Gli2-mediated antiinflammato-
ry action in skin CD4+ T cells. (A–C and F) RNA-seq; data sets from 2 inde-
pendent experimental groups of FACS-sorted pooled skin CD4+ T cells from 
Oxa-treated WT (n = 3), Gli2ΔN2 (n = 3), and Gli2ΔC2 (n = 3) mice. (A) PCA 
shows PC2 for WT (blue) and Gli2ΔC2 (green) mice; PC1 for WT (blue) and 
Gli2ΔN2 (red) mice. (B) Intersection of 3000 genes that contributed most 
to PC2 and 1500 most significant DEGs between WT and Gli2ΔC2 mice. 
(C) Intersection of 3000 genes that contributed most to PC1 and 2500 
most significant DEGs between WT and Gli2ΔN2 mice. (B and C) Heat-
maps cluster intersection genes; green is lower expression; red is higher 
expression. (D) Representative contour plots show CD4 against CD8 (left); 
CD25 against Foxp3 (gated on CD4+) (right) from Oxa-treated skin from 
WT and Gli2ΔN2 (top) mice; and WT and Gli2ΔC2 (bottom) mice. Plots 
show percentage of Tregs (of skin CD4+ T cells) in WT (black) or Gli2ΔN2 
or Gli2ΔC2 (red). (E) Percentage of CD25+Foxp3+, gated on skin CD4+ from 
Oxa-treated littermates. Left: WT (black), Gli3+/– (red). Right: WT (black), 
Shh+/– (red). (F) Expression of immune regulation genes from Gli2ΔN2 
(blue) and Gli2ΔC2 (red) RNA-seq. (G) Il10 and Tgfb1 expression (QRT-PCR) 
in Oxa-treated ear homogenates from littermates: WT (black) and Gli2ΔN2 
(red) (left); WT (black) and Gli2ΔC2 (red) (right); 2 independent exper-
iments. (H) Two independent experiments. Top: WT-CD4+CD25– T cells 
cocultured with CD4+CD25+ cells from Oxa-treated Gli2ΔC2 and WT spleens 
and WT-CD4+CD25– proliferation (CFSE staining). Plot shows percentage 
of nonproliferating cells on addition of WT-Tregs (black) and Gli2ΔC2-Tregs 
(red). Bottom: WT-CD4+CD25– T cells cocultured (1:1) with CD4+CD25+ cells 
from Oxa-treated Gli2ΔN2 and WT spleens. Plot shows percentage of cells 
that underwent divisions (CFSE staining) for WT-Tregs (black) and Gli2ΔN2-
Tregs (red). Representative histograms show cell divisions without Tregs 
(left) and divisions cocultured 1:1 (right) with WT-Tregs (red) and Gli2ΔC2-
Tregs (blue). Plots show mean ± SEM; for D–E, G, and H (bottom) each 
symbol represents an individual animal; 2-tailed unpaired Student’s t test. 
*P < 0.05, ***P < 0.001.
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Shh+/– skin increased AD severity, but increasing Shh expression 
in Gli3+/– skin decreased AD severity, we hypothesized that indi-
viduals who suffer from AD might have lower baseline levels of 
expression of Hh pathway components in skin than healthy indi-
viduals. To test this, we compared levels of expression of Hh path-
way components in transcriptome data sets from healthy donors 
and from healthy (nonlesional) skin from individuals who suffer 
from AD (GEO GSE32924) (49). Although we found no significant 
differences in expression of SHH, IHH, or DHH, mean expression 
levels of key components of the pathway, including the nonre-
dundant signal transducer SMO and the Hh coreceptors CDO and 
GAS1, were lower in nonlesional skin from AD patients than in skin 
from healthy controls (Figure 8G), suggesting that baseline levels 
of Hh signaling are indeed lower in humans who suffer from AD. 
Mean expression of several other genes known to interact with the 
pathway or are SHH target genes were also lower in nonlesional 
skin from AD patients than in skin from healthy controls (Figure 
8G) (28, 50–53). We then compared gene expression in lesional 
skin from AD patients to healthy (nonlesional) skin from the same 
individuals. Expression of several known SHH target genes (20, 
24, 34, 54, 55) was increased in lesional skin compared with non-
lesional skin from the same individuals (Figure 8G), suggestive of 
increased activation of the pathway in inflamed skin.
Discussion
Here we demonstrate that Shh signaling regulates the skin T cell 
immune response in AD. Cross-talk between epithelial cells and 
lymphocytes is essential for maintenance of skin homeostasis, 
and disruption of skin barrier function together with immune dys-
regulation lead to AD. Our experiments show that in the skin the 
morphogen Shh signals to CD4+ T cells to induce active regulatory 
T cell function and prevent inflammation, protecting against AD.
We showed that Shh was upregulated in skin on induction of 
AD and that this was protective against disease pathology and skin 
inflammation. The levels of Shh expression determined disease 
outcome. When Shh expression was lowered below WT levels in 
Shh+/– mice, AD was more severe, but when Shh was increased 
to above WT levels in Gli3+/– mice, AD was ameliorated. Thus, 
in humans, genetic factors that determine degree of Hh pathway 
activation in skin are likely to influence susceptibility to AD, and 
Hh-activating molecules might offer a new therapeutic approach. 
In support of this, analysis of human transcriptome data sets 
showed that baseline levels of key components of the Hh signaling 
pathway were expressed at lower levels in nonlesional skin of AD 
sufferers than in healthy control skin, indicating that Hh signaling 
may also be protective in human AD. In addition, genome wide 
association (GWAS) studies have identified the kinesin family 
member KIF3A as a susceptibility gene for AD (56, 57). KIF3A is 
required for translocation of SMO in the primary cilium on SHH 
signal transduction (10), so its identification in GWAS further sup-
ports the involvement of Hh signaling in human AD.
AD is a T cell–dependent disease and we showed that the anti-
inflammatory action of Shh was orchestrated by T cells, as when 
normal Hh pathway activation was conditionally inhibited in T cells 
all parameters of disease progression, severity, and pathology were 
increased. Hh-mediated transcription in response to Shh upregula-
tion increased skin CD4+ Treg function, activated TGF-β produc-
the reduced LAP expression, dampened TGF-β, and compromised 
cell-mediated suppression of Gli2ΔC2 Tregs in vitro and in vivo, 
we measured TGF-β signal transduction in skin Teff populations 
by staining against pSmad2/3. Skin CD4+ and CD8+ T cells from 
Oxa-treated Gli2ΔC2 mice showed decreased pSmad2/3 expres-
sion compared with WT mice, whereas skin CD4+ and CD8+ T cells 
from Oxa-treated Gli2ΔN2 mice had increased pSmad2/3 expres-
sion compared with WT mice (Figure 8, D and E), indicating that 
TGF-β production requires Hh-dependent Treg function in chron-
ic AD and TGF-β signals directly to skin Teffs.
Taken together, our data demonstrate that Hh signaling induc-
es and maintains functional Treg populations in the skin, leading 
to upregulation and activation of TGF-β, thus identifying a mech-
anism by which Gli2 activity in CD4+ T cells can control skin-spe-
cific immune responses and inflammation and reduce chronic AD.
Shh induced human Treg differentiation in vitro. Given the pro-
tective function of Shh and Hh signaling in our in-bred mouse 
model, we wanted to extrapolate our study to human AD. As 
Hh pathway activation induced Treg differentiation and Foxp3 
expression in mice (Figure 6, A–F), we tested if this is also the case 
in human T cells in vitro. We purified naive human CD4+ T cells 
from 4 independent randomly selected unknown donors and cul-
tured them for 5 days under iTreg conditions (plate-bound anti-
CD3, soluble anti-CD28, IL-2, and TGF-β1) in the presence of rShh 
or without addition of rShh (control). Gating on CD4+CD25+, the 
addition of rShh increased the expression of FOXP3 in cultures 
from all 4 independent donors (Figure 8F), suggesting that Shh 
can promote Treg differentiation in human T cells.
Expression of Hh pathway components in human skin from 
healthy donors and AD patients. As Shh treatment increased human 
Treg differentiation in vitro, and in mice, decreasing Hh levels in 
Figure 7. Hh signaling promotes skin Treg populations and their 
immune-regulatory function. (A–F) Groups of Gli2ΔN2 mice (7 per group 
unless stated otherwise) were injected in vivo with anti-CD25 antibody 
(red) or control IgG (black) 4 days before initiation of the Oxa protocol and 
again on day 7 (Supplemental Figure 5D). (A) Representative H&E images 
of skin sections from Oxa-treated anti-CD25–injected (n = 3) and control 
(IgG-injected, n = 5) Gli2ΔN2 groups on day 14. Scale bar: 100 μm. Plots 
show dermal and epidermal thickness. (B) Percentage of Tregs (CD25+ 
icFoxp3+) (gated on CD4+) from ears of control and anti-CD25–treated 
groups (left). Percentage of CD4+T cells and CD8+T cells (gated on live cells) 
from ears (center and right). (C) Serum IgE concentration (ELISA) from 
control and anti-CD25–treated groups. (D) Ifng, Il4, Il13, and Tgfb1 expres-
sion (QRT-PCR) in ear homogenates. (E) Percentage of skin CD4+ T cells 
that express cytokines. (F) Percentage of skin CD8+ T cells that express 
cytokines. (G–K) Adoptive transfer into Oxa-treated WT mice. Purified 
CD4+CD25+ (Tregs) from spleens of Oxa-treated Gli2ΔN2 (Gli2ΔN2 adoptive 
transfer group, n = 7, black) or Gli2ΔC2 mice (Gli2ΔC2 adoptive transfer 
group, n = 7, blue) were injected into WT mice 2 days before and on day 7 
of Oxa protocol (Supplemental Figure 5E), and compared with Oxa protocol 
WT control mice (control group; n = 7, red). (G) Ear thickness on days 5 to 14 
of the Oxa protocol of WT control, Gli2ΔN2 adoptive transfer, and Gli2ΔC2 
adoptive transfer groups (**P < 0.01 and ***P < 0.001, 2-tailed t test 
between WT control and Gli2ΔN2 adoptive transfer group). (H) Number of 
CD4+ T cells and CD8+ T cells recovered from ears from the 3 experimental 
groups. (I) Number of CD4+ T cells that expressed cytokines. (J) Number 
of CD8+ T cells that expressed cytokines. (K) Ifng, Il4, Il10, Tgfb1, and Shh 
expression (QRT-PCR) in ear homogenates. Two-tailed unpaired Student’s 
t test. (I–K) One-way ANOVA; each symbol represents an individual animal, 
showing mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
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Hh pathway activation in T cells in the lung exacerbates allergic 
asthma by promoting Th2 differentiation (23, 25). The fact that 
Shh is a morphogen that signals for distinct functions dependent 
on strength and duration of signal might account for its different 
roles in AD and asthma, and our experiments highlight the con-
text dependency of Shh’s functions and the tissue specificity of 
immune regulation by CD4+ T cells. An antiinflammatory action 
of Hh signaling has been described in other tissues (64–70), and 
here we demonstrate the beneficial consequences of Shh upreg-
ulation in AD. Additionally, we show that the antiinflammatory 
action of Shh in AD is orchestrated by T cells, and dissect the T cell 
intrinsic mechanisms of protection.
Aberrant Hh protein expression or dysregulated Hh signaling 
is involved in epithelial-derived tumors, including BCC (12, 13). 
We showed that inhibition of the Hh pathway both by pharmaco-
logical blockade and by genetic T cell–specific inhibition of endog-
enous Hh-mediated transcription increased IFN-γ production in 
skin CD4+ and CD8+ T cells. This is consistent with a recent study 
in which pharmacological Hh pathway inhibition resulted in BCC 
regression and a concomitant increase in IFN-γ+CD8+ infiltration 
(71). As Shh signals to induce regulatory functions in skin T cells, 
our study indicates that Hh secretion might be a mechanism of 
immune evasion by skin tumors. Inhibition of Shh-signaling in 
skin cancers will therefore have the additional benefit of releasing 
T cells to generate an immune response against the tumor.
As well as highlighting that Hh-mediated transcription in T 
cells promotes TGF-β signaling to dampen skin inflammation, our 
RNA-seq of CD4+ T cells from AD skin showed that Hh reduced 
expression of Ccl24 and Ccl8, and these chemokines recruit eosin-
ophils to the skin (72). Hh also reduced expression of other genes 
for inflammatory signaling pathways implicated in skin inflam-
mation including TNFR (Tnfrsf25), JAK-STAT (Jak1), and NF-κB 
(Trl4, Myd88, Cd69, Cd48, Irf1).
Research into therapies for AD has focused on targeting Th2 
cytokines (73). The observation that Shh is upregulated in skin 
after AD induction and that Gli-dependent Hh pathway activation 
in T cells suppresses proinflammatory cytokine production and 
restores functional Treg populations, is important for develop-
ment of new strategies to treat AD.
Methods
Mice and atopic dermatitis model by chronic hapten application. GBS-
GFP transgenic mice (27) were provided by J. Briscoe (Francis Crick 
Institute, London, United Kingdom) and Shh+/– mice were provided 
by P. Beachy (Stanford University, Stanford, California, USA) (74). 
C57BL/6 mice were purchased from Envigo; Gli3+/– and Rag1-KO 
mice were from the Jackson Laboratory. Lck-Gli2ΔN2 and Lck-
Gli2ΔC2 transgenic mice were as described (17, 18). Mice were fully 
backcrossed onto C57/BL6 and maintained in specific pathogen-free 
conditions at UCL.
Chronic AD was induced as described (75). Six- to 8-week-old 
mice were sensitized on the shaved abdomen with 3% of the hapten 
4-ethoxymethylene-2-phenyloxazolin-5-one (Oxa, Sigma) and chal-
lenged topically on the ears with 5 doses of 0.6% Oxa on days 5, 7, 9, 
11, and 13. Mice were sacrificed and analyzed on day 14 (Figure 1A). 
For controls, vehicle (ethanol) alone was applied. This protocol was 
used in all experiments and is referred to as Oxa treatment. All analy-
tion, and promoted TGF-β signaling to other skin T cells, thereby 
decreasing skin proinflammatory responses. This was supported 
by in vivo experiments that showed that adoptive transfer of Tregs 
from Oxa-treated Gli2ΔN2 animals was sufficient to prevent AD 
in Oxa-treated WT animals, whereas adoptive transfer of Tregs in 
which the Hh signaling pathway is inhibited (Oxa-treated Gli2ΔC2) 
was unable to reduce AD, highlighting the essential role of Hh path-
way activation for immune regulation on induction of AD.
RNA-seq demonstrated that Hh-mediated transcription in skin 
CD4+ T cells on induction of AD increased expression of immu-
noregulatory genes (including Ptgs2, Il10, Klrg1, Areg, and Fgl2) 
and decreased expression of inflammatory and migratory genes 
(Tnfrsf9, Il1a, Tgif1, Ccr7, Ccr9, Ccl20, and Ccl24). The observa-
tion that increased Hh pathway activation restores the immuno-
suppressive phenotype of skin Tregs is important for treatments 
for AD, because nonfunctional Tregs are strongly correlated with 
skin inflammation in mouse models and human patients (5–8, 58).
Notch and Wnt signaling are also involved in skin inflamma-
tion. Loss of Notch signaling results in disruption of the epider-
mal skin barrier and inflammatory skin disease (59, 60), where-
as the Wnt pathway can drive skin inflammatory responses and 
is induced in psoriasis (61–63). Genes encoding components of 
Wnt (Tcf4, Wnt4) and Notch pathways (Dtx1, Hes, Dtx3, Lfng) were 
differentially expressed between genotypes in our RNA-seq data 
sets, suggesting crosstalk between Hh signaling and these other 
developmental pathways in skin T cells.
In contrast to the demonstrated protective role of Shh upreg-
ulation on induction of chronic AD, increased Shh expression and 
Figure 8. Hh signaling promotes immune-regulatory function through 
TGF-β. Hedgehog signaling and human AD. (A–E) Two independent exper-
iments with at least 6 mice per group. (A) Percentage of LAP+ cells, gated 
on CD45+CD3– and CD4+CD25– (non-Treg) from skin of Oxa-treated Gli2ΔN2 
(black), WT (red), and Gli2ΔC2 (blue) mice. (B) Representative histograms 
show anti-LAP staining on skin Tregs from Oxa-treated littermates. 
Plots show number of LAP+ Tregs in WT (black) littermates and Gli2ΔN2 
(red) (left) or Gli2ΔC2 (red) (right). (C) Active TGF-β concentration (ELISA) 
in culture supernatants. CD4+CD25– splenocytes from WT (black) and 
Gli2ΔC2 (red) mice, cultured alone (left). WT CD4+ T cells cultured 1:1 with 
FACS-sorted Tregs (CD4+CD25+) from Oxa-treated WT (black) and Gli2ΔC2 
(red) mice (right). (D and E) Representative FACS plots show pSmad2/3 
expression in skin (D) CD4+ and (E) CD8+ (gated on CD45+CD3+γδTCR–) from 
Oxa-treated WT and Gli2ΔC2 mice (left); and WT and Gli2ΔN2 mice (right). 
Plots show MFI of anti-pSmad2/3 in skin CD4+ (left) and CD8+ (right) from 
Gli2ΔN2 (black), WT (red), and Gli2ΔC2 (blue) Oxa-treated groups (1-way 
ANOVA). (F) Naive CD4+ cells from 4 randomly selected unknown leuko-
cyte-cone donors cultured for 5 days under iTreg conditions in presence 
or absence of rShh (labeled iTregs). Dot-plot shows representative CD4 
and CD25 expression. Histogram shows representative icFOXP3 expres-
sion, gated on CD4+CD25+ and giving percentage of cells in marker shown. 
Scatter plot shows percentage of FOXP3+ cells gated on CD4+CD25+ from 
cultures from 4 independent donors; 2-tailed paired t test. (G) Scatter plots 
show expression (RPKM) from publicly available RNA-seq data sets (GEO 
GSE32924) from human healthy skin (red, n = 8), and nonlesional (blue) 
and lesional (green) skin from AD patients (n = 12). Expression of genes 
encoding Hh pathway components and regulators in healthy skin and 
nonlesional skin from AD patients (left). Expression of Hh target genes 
in nonlesional and lesional skin from AD patients (2-tailed paired t test) 
(right). Two-tailed unpaired Student’s t test unless stated otherwise; plots 
are mean ± SEM, each symbol represents a different individual. *P < 0.05, 
**P < 0.01, ***P < 0.001, ****P < 0.0001.
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upright 3-color microscope (×10 magnification). Quantification of 
dermal/epidermal thickness and immunofluorescence image analysis 
were carried out using Fiji software.
In vitro Treg cell suppression assay. CD4+CD25– T cells and 
CD4+CD25+ Treg cells from WT and Gli2ΔC2 spleens of Oxa-treat-
ed mice were FACS-sorted. WT CD4+ T cells were first stained with 
CFSE and then cocultured with Tregs at 1:1 and 1:4 ratios as described 
(77) for 4 days.
Measurement of IgE and cytokines. Serum was obtained and IgE levels 
measured by ELISA (eBioscience kit) as described (78) according to the 
manufacturer’s instructions. Supernatants were collected after 4 days of 
coculture of CD4+ T cells and Tregs. Active TGF-β levels were measured 
by ELISA (Invitrogen) according to the manufacturer’s instructions.
Ear pinnae were homogenized and centrifuged at 2330 g for 20 
minutes to collect skin supernatants. Cytokines from homogenates 
were measured by multiplex immunoassays using Firefly from Abcam, 
according to the manufacturer’s protocol.
Human samples. Human peripheral blood mononuclear cells 
(PBMCs) were freshly isolated using Ficoll-Paque (MilliporeSigma) 
from randomly selected unknown leukocyte-cone donors from the Unit-
ed Kingdom NHS Blood and Transplant Centre. After magnetic separa-
tion (EasySep Isolation Kit, StemCell), naive CD4+ T cells (CD3+CD4+ 
CD45RA+CD45RO–) were differentiated under iTreg conditions at 1 × 
106 cells/mL. Cells were stimulated with plate-bound anti-CD3 (5 μg/
mL, UCHT1; eBioscience), soluble anti-CD28 (1 μg/mL, eBioscience), 
IL-2 (100 IU/mL, eBioscience) and TGF-β1 (5 ng/mL, Peprotech). 
Recombinant Shh (0.5 μg/mL, R&D Systems) was added, cells were 
incubated for 5 days and analyzed for intracellular FOXP3 expression.
RNA extraction and quantitative RT-PCR (QRT-PCR) analysis. 
RNA was extracted using the Arcturus PicoPure RNA isolation kit 
(Applied Biosystems), following the manufacturer’s instructions. RNA 
conversion to cDNA and QRT-PCR were as described (78), using prim-
ers purchased from Qiagen.
RNA-sequencing. After induction of AD by the Oxa protocol, skin 
cell suspensions from 2 groups of 3 mice each from WT, Gli2ΔN2, and 
Gli2ΔC2 mice were obtained. Cells were stained and live cells sort-
ed (CD45+CD3+γδTCR–CD4+CD8–), RNA extracted, and RNA quality 
determined with a Bioanalyzer 2100 (Agilent Technologies). cDNA 
conversion and RNA-seq, performed by UCL Genomics on a NextSeq 
500 system (Illumina), were as described (28). All RNAsequencing 
data were deposited in the NCBI’s Gene Expression Omnibus database 
(GEO GSE117338). The normalized estimates of transcript abundance 
expressed as RPKM (reads per kilobase of transcripts per million mapped 
reads) were generated using the Bioconductor package DESeq2. DEGs 
were determined using Ebayes analysis (P < 0.05) from the limma pack-
age in Bioconductor. CRAN package ade4 was used for PCA analysis.
Statistics. An unpaired 2-tailed Student’s t test was performed for 
comparison of the experimental groups, unless otherwise stated. For 
statistical analysis of multiple comparisons ANOVA was used where 
stated. For data shown in Figure 8, F and G (left), paired 2-tailed t test 
was used. P less than 0.05 was considered statistically significant.
Study approval. Mouse studies were carried out under UK Home 
Office regulations, following ethical review at University College Lon-
don. Experiments with human cells were ethically approved by the 
area NHS Research Ethics Committee. Cells were obtained from leu-
kocyte cones from anonymous donors to our national blood service, so 
informed consent to take part in this specific study was not required.
ses were made on termination on day 14, unless otherwise stated. Ear 
thickness was measured with a micrometer (Mitutoyo).
In some experiments, mice were injected i.p. with 40 μg/day of 
Smo-inh, PF-04449913 (Pfizer), or vehicle control (DMSO) for 14 
days (Figure 3A).
Tissue processing and flow cytometry. Spleens and skin-draining 
LNs were processed and stained as described (35), using antibodies 
listed in Supplemental Table 4. Cell counting was performed on an 
Accuri C6 (BD Biosciences) and/or hemocytometer. To release leuko-
cytes from ear tissue, ears were split into dorsal and ventral halves and 
digested for 30 minutes at 37°C with 1 mg/mL Collagenase D (Roche) 
and 0.5 mg/mL DNase I (Roche) in RPMI (Life Technologies) con-
taining 2%FCS (Life Technologies) and 2% penicillin/streptomycin 
(Life Technologies), filtered through a 70-μm cell strainer (VWR) and 
washed in RPMI containing 10% FCS and 5% penicillin/streptomycin. 
Intracellular cytokine staining was performed after restimulation of 
cells in complete RPMI (cRPMI) with cell activation cocktail (Bioleg-
end) for 4 hours at 37°C. Cells were first surface stained, fixed/perme-
abilized using the eBioscience Fixation/Permeabilization kit accord-
ing to the manufacturer’s instructions, and then stained for cytokines.
For pSmad2/3 staining, cells were stimulated for 45 minutes with 
rTGF-β (5 ng/mL) in RPMI at 37°C and 5% CO2, then fixed with BD 
PhosphoFlow PermBufferII according to the manufacturer’s instruc-
tions, washed with PBS, and permeabilized with ice-cold BD Phospho-
Flow PermBufferIII for 30 minutes according to the manufacturer’s 
instructions. To block unspecific binding, cells were treated with 1.5% 
donkey serum (MilliporeSigma) in PBS for 30 minutes. After washing 
with PBS, cells were incubated with primary anti-Smad2/3 antibody 
(1:50) for 1 hour before incubation with donkey anti-rabbit–PE second-
ary antibody (1:200) and other antibodies of interest for 45 minutes.
Dead cells were excluded using the Zombie Aqua Fixable Viability 
kit (Biolegend). Cells were analyzed on LSRII (BD Biosciences). Data 
were analyzed using FlowJo 10.4.1 (Tree Star).
Treg neutralization in vivo and Treg adoptive transfer. For Treg 
neutralization, Tregs from Lck-Gli2ΔN2 mice were depleted in vivo 
using 100 μg anti-CD25 antibody (PC61, Biolegend) and control Lck-
Gli2ΔN2 mice were injected with 100 μg rat IgG (Biolegend) 4 days 
before the Oxa treatment and on day 7 (Supplemental Figure 5D).
For adoptive transfer experiments, Gli2ΔN2 and Gli2ΔC2 Tregs 
from spleens of Oxa-treated mice were magnetically isolated (Easy-
Sep Mouse CD4+CD25+ Regulatory T cell isolation kit II, StemCell) 
and 200,000 Gli2ΔN2 Tregs or 200,000 Gli2ΔC2 Tregs were inject-
ed i.p. into WT mice 2 days before and on day 7 of Oxa treatment (Sup-
plemental Figure 5E). WT Oxa-treated control mice were injected with 
PBS. Mice were analyzed on day 14.
Histological analysis of skin. Ear pinnae sections were fixed in Bou-
in’s solution (MilliporeSigma). H&E staining was as described (76). 
Images were taken using a Zeiss Axioplan microscope (×10 magnifi-
cation). For immunofluorescence, ear sections were frozen in OCT 
(Thermo Fisher Scientific) and cut into 7.5-μm sections. Nonspecif-
ic binding was blocked by incubation with 0.2% fish gelatin (Milli-
poreSigma) and 0.1% Tween (BioRad) in PBS (Life Technologies). 
Cells were stained with primary unconjugated anti-Shh (1:50 dilution; 
171018; Santa Cruz Biotechnology), followed by incubation with don-
key anti-goat IgG Alexa Fluor 594 (1:500 dilution; Invitrogen) sec-
ondary antibody in blocking buffer. Slides were mounted with Gold 
antifade reagent with DAPI (Invitrogen) and visualized using a Leica 
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